Overexpression TRIM40 for inhibiting proliferation, migration and invasion of pancreatic cancer cells and application of over-expression TRIM40

By overexpressing TRIM40, it inhibits the proliferation and migration of pancreatic cancer cells, solves the problem of pancreatic cancer treatment, provides new therapeutic ideas and molecular targets for pancreatic cancer, and improves the targetedness and effectiveness of the treatment.

CN118995630APending Publication Date: 2024-11-22广州医科大学附属清远医院(清远市人民医院)
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410902356.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-06
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

There are great challenges in the diagnosis and treatment of pancreatic cancer, especially due to its high invasiveness and drug resistance, existing chemotherapy and radiotherapy effects are limited, and there is a lack of effective molecular targets and therapeutic pathways.

Method used

By overexpressing TRIM40, the proliferation, migration and invasion of pancreatic cancer cells was inhibited, and the ROCK1 signaling pathway was regulated by TRIM40's E3 ubiquitin ligase activity was used to construct a pancreatic cancer cell model that was stable overexpressing TRIM40, and screen and evaluate gene therapy drugs. Effect of TRIM40 on cell cycle.

Benefits of technology

It significantly inhibits the proliferation, migration and invasion ability of pancreatic cancer cells, provides new therapeutic ideas and molecular targets for pancreatic cancer, improves the targetedness and effectiveness of the treatment, and provides experimental basis and methods for personalized treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995630A_ABST
    Figure CN118995630A_ABST
Patent Text Reader

Abstract

The invention discloses an overexpression TRIM40 for inhibiting proliferation, migration and invasion of pancreatic cancer cells and application of the overexpression TRIM40, belongs to the technical field of biomedicine, confirms expression of TRIM40 in pancreatic cancer cells, discovers that the overexpression of TRIM40 can inhibit proliferation, migration and invasion of cancer cells, and provides a new thought for pancreatic cancer treatment. The invention also provides a method for screening gene therapy drugs by using a TRIM40 overexpression model, provides a basis for personalized therapy, researches and discusses the influence of TRIM40 on the cell cycle, reveals the action mechanism of TRIM40 in tumor development, and finally provides a method for carrying out in-vitro drug sensitivity test by using the model. Effective drugs are rapidly screened, research and development time is shortened, cost is reduced, an accurate basis is provided for treatment scheme selection, in conclusion, new molecular targets and strategies are provided for pancreatic cancer, experimental basis and methods are provided for personalized treatment and drug research and development, and the survival rate and life quality of patients are expected to be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, and specifically relates to an overexpression of TRIM40 to inhibit the proliferation, migration and invasion of pancreatic cancer cells and an application thereof. Background Art

[0002] Pancreatic cancer is recognized as one of the most aggressive and lethal cancers worldwide, with an extremely low 5-year survival rate, mainly because it is usually diagnosed in the late stage and is highly resistant to existing chemotherapy and radiotherapy. Therefore, exploring new molecular targets and therapeutic pathways is crucial to improving the survival rate of pancreatic cancer patients.

[0003] As a member of the TRIM protein family, TRIM40 has E3 ubiquitin ligase activity and is involved in regulating a variety of intracellular processes, including cell proliferation, apoptosis, autophagy, and immune response, which indicates that TRIM40 may play an important role in different biological processes. Although some members of the TRIM family have been shown to promote or inhibit tumor development in other types of cancer, the role and mechanism of TRIM40 in pancreatic cancer are still unclear.

[0004] Recent studies have shown that TRIM40 can regulate the development of inflammatory bowel disease by targeting and degrading ROCK1, suggesting its potential in regulating cell signaling pathways. However, how the expression level of TRIM40 changes in pancreatic cancer cells and how this change affects the biological behavior of pancreatic cancer cells has not been reported in detail.

[0005] In view of this, this study aims to explore the expression of TRIM40 in pancreatic cancer cells and analyze its effects on the biological behaviors of pancreatic cancer cell MIA PaCa-2, such as proliferation, migration, invasion and clone formation, by overexpressing TRIM40. Through this series of experimental designs, we can not only deeply understand the potential role of TRIM40 in pancreatic cancer, but also provide new molecular targets and strategies for the diagnosis and treatment of pancreatic cancer. Summary of the invention

[0006] The purpose of the present invention is to provide a method for overexpressing TRIM40 to inhibit the proliferation, migration and invasion of pancreatic cancer cells and its application, so as to solve the problems raised in the above background technology.

[0007] To achieve the above object, the present invention provides the following technical solution: a method for overexpressing TRIM40 to inhibit the proliferation, migration and invasion of pancreatic cancer cells and its application, the method comprising the following steps:

[0008] A. Provide a pancreatic cancer cell line, such as MIA PaCa-2 or PANC-1, cultured in a freshly prepared DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, cultured at 37° C., 5% CO2, cultured to a certain density, i.e., about 80%, and then taking cells in the logarithmic growth phase for subsequent inoculation treatment;

[0009] B. Construct a stable cell line. Take MIA PaCa-2 cells in the logarithmic growth phase and inoculate them into a 24-well plate. After culturing at 37°C and 5% CO2 for 16-24 hours, the cells can be infected when the confluence is about 50-60%. After 16 hours, change the medium. 72 hours after infection, observe the fluorescence intensity and determine the transfection efficiency.

[0010] C. qRT-PCR experiment, total RNA was extracted by Trizol method and reverse transcribed into cDNA using reverse transcription kit (Takara). qRT-PCR was performed in PCR instrument using SYBR Green qPCR method. GAPDH was used as internal reference and 2- ΔΔ The relative expression level was calculated by Ct method;

[0011] D. Western Blot experiment: MIA PaCa-2 and PANC-1 cells with good growth status were collected, RIPA lysis buffer was added to extract proteins, and the concentration was measured and quantified using the BCA kit;

[0012] The removed SDS-PAGE gel was fixed in the electrophoresis tank, and 30 ng of total protein was loaded, and electrophoresis was performed at a constant voltage of 160 V for 50 min. The separated proteins were then transferred to the membrane using a wet method, and the transferred PVDF membrane was blocked in 5% skim milk at room temperature for 2 h, washed three times with TBST 10 min / time, and incubated slowly overnight at 4°C with TRIM40 (1:3000) or GAPDH (1:10000) antibodies;

[0013] After 24 hours, the membrane was removed and washed three times with TBST, and the secondary antibody (1:10000) was added and incubated on a shaker at room temperature for 2 hours, and the gel imager was used for development and imaging.

[0014] E. Immunofluorescence assay, PANC-1 and MIA PaCa-2 cells were plated in the center of an immunofluorescence dish, cultured for 24 h, washed with PBS for 5 min, washed three times, fixed with paraformaldehyde for 30 min, washed again with PBS, permeabilized with Triton X-100 for 5 min, washed with PBS, blocked with 5% BSA for 2 h, and then incubated with TRIM40 (1:200) antibody prepared with 1% BSA at 4°C overnight;

[0015] After 24 hours, the cells were washed with PBST, incubated with rabbit secondary antibody (1:500) for 2 hours in the dark, washed three times with PBST, stained nuclei with DAPI for 5 minutes in the dark, washed with PBST, and the expression and localization of TRIM40 were observed under a confocal microscope and photographed.

[0016] F. Cell proliferation assay: Digest and dilute the cells in the logarithmic growth phase to prepare 1000 cells / well (1x10 4 / ml) of cell suspension was inoculated into 96-well plates at 100ul / well, with at least 3 replicates per group, and cultured in an incubator at 37°C and 5% CO2;

[0017] After 48 hours, 10ul of CCK8 reagent was added to each well, and the cells were incubated in a dark incubator for 2 hours. The absorbance was measured at 450nm using an ELISA reader for statistical analysis.

[0018] G. For clone formation experiments, cells in the logarithmic growth phase were digested and diluted to prepare a cell suspension of 1000 cells / well, inoculated into a six-well plate, and cultured in an incubator at 37°C and 5% CO2. The medium was changed every 3 days for 14 consecutive days. After washing with PBS, the cells were fixed with paraformaldehyde for 15 minutes, stained with 1% crystal violet for 15 minutes, and photographed after drying;

[0019] H. Cell scratch test: Digest and dilute the cells in the logarithmic growth phase to prepare 3.5x10 4 70ul of cell suspension was evenly spread on the wound healing plug. When the cell confluence reached about 90%, the wound healing plug was removed, washed with PBS, and culture medium was added. Pictures were taken at 0h and 24h respectively.

[0020] I. Migration experiment: Add 1x10 5 Cells suspended in 100ul serum-free medium were added to the lower chamber, and 600ul complete medium was added to the lower chamber. After culturing in an incubator at 37°C and 5% CO2 for 48h, the chamber was removed, washed 3 times with PBS, fixed with 4% paraformaldehyde for 30min, stained with 1% crystal violet for 5min, and the cells that did not pass through the upper chamber were wiped off with a wet cotton swab and washed with PBS. The cells were observed, photographed and counted under an inverted microscope;

[0021] J. Invasion assay: 100ul of matrix gel was pre-coated on the upper chamber membrane of the Transwell and allowed to stand at 37°C for 2 hours. After solidification, the excess matrix gel was removed. The subsequent steps were the same as those of the migration assay;

[0022] Statistics and analysis: GraphPad Prism 8.0 software was used for statistical analysis, and the data were expressed as mean ± standard deviation. The two groups were compared using paired t-test, and P < 0.05 was considered statistically significant.

[0023] Preferably, a method for screening and evaluating gene therapy drugs for a pancreatic cancer cell line overexpressing TRIM40 comprises the following steps: culturing a pancreatic cancer cell line overexpressing TRIM40 according to the culturing and treatment method of claim 1; introducing the gene therapy drug to be tested into the cells; detecting changes in cell proliferation, migration or invasion; and comparing the effect with that of an untreated control group to evaluate the effect of the gene therapy drug on inhibiting the growth of pancreatic cancer cells.

[0024] Preferably, a method for performing cell cycle analysis on a pancreatic cancer cell model that overexpresses TRIM40 comprises: culturing pancreatic cancer cells according to the method of claim 1 and causing them to overexpress TRIM40; then using flow cytometry or other cell cycle analysis techniques to analyze the cell cycle stages of cells that overexpress TRIM40; and evaluating the effect of TRIM40 on the cell cycle of pancreatic cancer cells by comparing the differences in cell cycle distribution between cells that overexpress TRIM40 and cells with normal TRIM40 expression levels.

[0025] Preferably, a method for using pancreatic cancer cells overexpressing TRIM40 in an in vitro drug sensitivity test comprises: providing pancreatic cancer cells overexpressing TRIM40 prepared according to claim 1; subjecting the cells to a series of chemotherapeutic drugs or targeted therapeutic agents with a concentration gradient; evaluating the drug sensitivity of pancreatic cancer cells overexpressing TRIM40 by different drugs by measuring cell survival rate, apoptosis rate or expression changes of related markers, and comparing with wild-type cells, thereby screening out potential effective therapeutic drugs.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] First, this study confirmed the expression of TRIM40 in pancreatic cancer cells through experimental means, and found that overexpression of TRIM40 can significantly inhibit the proliferation, migration and invasion of pancreatic cancer cells. This discovery provides a new idea for the treatment of pancreatic cancer. Traditional chemotherapy and radiotherapy have limited therapeutic effects on pancreatic cancer and are often accompanied by serious side effects. Inhibiting the growth of pancreatic cancer cells by regulating the expression of TRIM40 may become a more accurate and low-side effect treatment method. Secondly, the method proposed in this case for screening and evaluating gene therapy drugs using a pancreatic cancer cell model overexpressing TRIM40 provides an experimental basis for personalized treatment of pancreatic cancer. Through this method, drugs with high inhibitory effects on specific pancreatic cancer cells can be screened, thereby improving the pertinence and effectiveness of treatment. In addition, this method can also be used to evaluate the effects of different drugs on pancreatic cancer cells, providing a reference for the selection of clinical treatment plans. Furthermore, this study also explored the effect of TRIM40 on the cell cycle of pancreatic cancer cells, which is of great significance for understanding the specific mechanism of TRIM40 inhibiting the growth of pancreatic cancer cells. Abnormal cell cycle is one of the important reasons for the occurrence and development of tumors. By analyzing the effect of TRIM40 on the cell cycle, its mechanism of action in the occurrence and development of pancreatic cancer can be revealed, providing a theoretical basis for subsequent research. Finally, this study also proposed the application of in vitro drug sensitivity testing using pancreatic cancer cells that overexpress TRIM40. This application can help researchers quickly screen out drugs that have a high inhibitory effect on pancreatic cancer cells, shorten the time of drug development, and reduce research and development costs. At the same time, this method can also be used to evaluate the drug sensitivity of different drugs to pancreatic cancer cells, providing a more accurate basis for the selection of clinical treatment options. In summary, the research in this case not only provides new molecular targets and strategies for the treatment of pancreatic cancer, but also provides an experimental basis and method for personalized treatment and drug development of pancreatic cancer. This is expected to provide new hope for improving the survival rate and quality of life of pancreatic cancer patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The expression level of TRIM40 protein in pancreatic cancer cells and the expression and localization of TRIM40 protein were shown in this study;

[0029] Figure 2 This is a graph showing the transfection efficiency of MIA PaCa-2 cells overexpressing TRIM40 according to the present invention;

[0030] Figure 3 This is a graph showing changes in proliferation and clone formation ability of MIA PaCa-2 cells after overexpression of TRIM40 in the present invention;

[0031] Figure 4This is a graph showing changes in the scratch healing ability of MIA PaCa-2 cells after overexpression of TRIM40 in the present invention;

[0032] Figure 5 This is a diagram showing changes in the migration and invasion abilities of MIA PaCa-2 cells after overexpression of TRIM40 in the present invention. DETAILED DESCRIPTION

[0033] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0034] See also Figure 1-Figure 5 The present invention provides a method for overexpressing TRIM40 to inhibit the proliferation, migration and invasion of pancreatic cancer cells and its application, the method comprising the following steps:

[0035] A. Provide a pancreatic cancer cell line, such as MIA PaCa-2 or PANC-1, cultured in a freshly prepared DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, cultured at 37° C., 5% CO2, cultured to a certain density, i.e., about 80%, and then taking cells in the logarithmic growth phase for subsequent inoculation treatment;

[0036] B. Construct a stable cell line. Take MIA PaCa-2 cells in the logarithmic growth phase and inoculate them into a 24-well plate. After culturing at 37°C and 5% CO2 for 16-24 hours, the cells can be infected when the confluence is about 50-60%. After 16 hours, change the medium. 72 hours after infection, observe the fluorescence intensity and determine the transfection efficiency.

[0037] C. qRT-PCR experiment, total RNA was extracted by Trizol method and reverse transcribed into cDNA using reverse transcription kit (Takara). qRT-PCR was performed in PCR instrument using SYBR Green qPCR method. GAPDH was used as internal reference and 2- ΔΔ The relative expression level was calculated by Ct method;

[0038] D. Western Blot experiment: MIA PaCa-2 and PANC-1 cells with good growth status were collected, RIPA lysis buffer was added to extract proteins, and the concentration was measured and quantified using the BCA kit;

[0039] The removed SDS-PAGE gel was fixed in the electrophoresis tank, and 30 ng of total protein was loaded, and electrophoresis was performed at a constant voltage of 160 V for 50 min. The separated proteins were then transferred to the membrane using a wet method, and the transferred PVDF membrane was blocked in 5% skim milk at room temperature for 2 h, washed three times with TBST 10 min / time, and incubated slowly overnight at 4°C with TRIM40 (1:3000) or GAPDH (1:10000) antibodies;

[0040] After 24 hours, the membrane was removed and washed three times with TBST, and the secondary antibody (1:10000) was added and incubated on a shaker at room temperature for 2 hours, and the gel imager was used for development and imaging.

[0041] E. Immunofluorescence assay, PANC-1 and MIA PaCa-2 cells were plated in the center of an immunofluorescence dish, cultured for 24 h, washed with PBS for 5 min, washed three times, fixed with paraformaldehyde for 30 min, washed again with PBS, permeabilized with Triton X-100 for 5 min, washed with PBS, blocked with 5% BSA for 2 h, and then incubated with TRIM40 (1:200) antibody prepared with 1% BSA at 4°C overnight;

[0042] After 24 hours, the cells were washed with PBST, incubated with rabbit secondary antibody (1:500) for 2 hours in the dark, washed three times with PBST, stained nuclei with DAPI for 5 minutes in the dark, washed with PBST, and the expression and localization of TRIM40 were observed under a confocal microscope and photographed.

[0043] F. Cell proliferation assay: Digest and dilute the cells in the logarithmic growth phase to prepare 1000 cells / well (1x10 4 / ml) of cell suspension was inoculated into 96-well plates at 100ul / well, with at least 3 replicates per group, and cultured in an incubator at 37°C and 5% CO2;

[0044] After 48 hours, 10ul of CCK8 reagent was added to each well, and the cells were incubated in a dark incubator for 2 hours. The absorbance was measured at 450nm using an ELISA reader for statistical analysis.

[0045] G. For clone formation experiments, cells in the logarithmic growth phase were digested and diluted to prepare a cell suspension of 1000 cells / well, inoculated into a six-well plate, and cultured in an incubator at 37°C and 5% CO2. The medium was changed every 3 days for 14 consecutive days. After washing with PBS, the cells were fixed with paraformaldehyde for 15 minutes, stained with 1% crystal violet for 15 minutes, and photographed after drying;

[0046] H. Cell scratch test: Digest and dilute the cells in the logarithmic growth phase to prepare 3.5x10 470ul of cell suspension was evenly spread on the wound healing plug. When the cell confluence reached about 90%, the wound healing plug was removed, washed with PBS, and culture medium was added. Pictures were taken at 0h and 24h respectively.

[0047] I. Migration experiment: Add 1x10 5 Cells suspended in 100ul serum-free medium were added to the lower chamber, and 600ul complete medium was added to the lower chamber. After culturing in an incubator at 37°C and 5% CO2 for 48h, the chamber was removed, washed 3 times with PBS, fixed with 4% paraformaldehyde for 30min, stained with 1% crystal violet for 5min, and the cells that did not pass through the upper chamber were wiped off with a wet cotton swab and washed with PBS. The cells were observed, photographed and counted under an inverted microscope;

[0048] J. Invasion assay: 100ul of matrix gel was pre-coated on the upper chamber membrane of the Transwell and allowed to stand at 37°C for 2 hours. After solidification, the excess matrix gel was removed. The subsequent steps were the same as those of the migration assay;

[0049] Statistics and analysis: GraphPad Prism 8.0 software was used for statistical analysis, and the data were expressed as mean ± standard deviation. The two groups were compared using paired t-test, and P < 0.05 was considered statistically significant.

[0050] Furthermore, a stable pancreatic cancer cell culture model was established to provide reliable cell resources for subsequent experiments. The use of specific culture medium and culture conditions can ensure that the cells grow well and consistently, thereby ensuring the accuracy and repeatability of the experimental results. In addition, the use of cells in the logarithmic growth phase can ensure the consistency of the physiological state of the cells used in the experiment, reduce experimental errors, and improve experimental efficiency and reliability.

[0051] By constructing a pancreatic cancer cell line that stably overexpresses TRIM40, the effect of TRIM40 on the behavior of pancreatic cancer cells can be observed over a long period of time. The establishment of a stable cell line is helpful for long-term drug screening and evaluation experiments, providing an important tool for studying the function of TRIM40 in pancreatic cancer, and laying a solid foundation for subsequent in vitro and in vivo experiments;

[0052] The accurate detection of TRIM40 expression at the mRNA level using qRT-PCR technology is crucial for monitoring the expression changes of TRIM40 and its impact on downstream gene regulation. This technology not only improves the sensitivity and accuracy of detection, but also can quickly analyze a large number of samples, effectively advancing the experimental process, and providing strong support for revealing the mechanism of action of TRIM40 in pancreatic cancer cells. Total RNA was extracted using the Trizol method and reverse transcribed into cDNA using a reverse transcription kit (Takara). qRT-PCR was performed using the SYBR Green qPCR method in a PCR instrument. GAPDH was used as an internal reference and 2- ΔΔ The relative expression level was calculated by Ct method;

[0053] Table 1Primer sequences for qRT-PCR

[0054]

[0055] The Western Blot experiment can be used to visually detect the expression level of TRIM40 protein in pancreatic cancer cells and verify the expression effect. The high specificity and sensitivity of this technology ensure the reliability of the experimental results and provide direct evidence for further exploring the effects of TRIM40 on the function of pancreatic cancer cells. At the same time, protein expression analysis can reveal the activation status of the signaling pathway of TRIM40 in pancreatic cancer cells, providing clues for mechanism research;

[0056] Using immunofluorescence to visualize the localization and expression pattern of TRIM40 protein in pancreatic cancer cells helps to understand its distribution within cells and its potential mode of action. The intuitive evidence provided by this method is crucial for analyzing how TRIM40 affects cell behavior and can help scientists further explore the specific biological processes in which it participates;

[0057] Evaluating the effect of TRIM40 on the proliferation ability of pancreatic cancer cells through cell proliferation experiments is a direct means to study its inhibitory effect on tumor growth. The use of CCK8 reagents makes the experimental operation simple and rapid, and can effectively evaluate cell viability and proliferation status, providing basic data for subsequent anticancer drug development and treatment strategy research;

[0058] The clone formation assay is an important method to evaluate cell proliferation and clone formation ability, reflecting the independent survival and proliferation potential of cells. This experiment provides important information for understanding how TRIM40 affects the malignant biological behavior of pancreatic cancer cells, and also helps to evaluate the effectiveness of therapeutic strategies targeting TRIM40 in inhibiting tumor regeneration;

[0059] The cell scratch test is an effective means to observe cell migration and wound healing ability, and is of great significance for studying how TRIM40 affects the migration behavior of pancreatic cancer cells. This experiment can intuitively show the regulatory effect of TRIM40 on cell migration ability, providing an experimental basis for further exploring its potential role in tumor metastasis;

[0060] The migration experiment is specifically used to evaluate the migration ability of cells and is one of the key experiments in studying the invasiveness of tumor cells. This experiment can evaluate the effect of TRIM40 on the migration behavior of pancreatic cancer cells and further reveal its role in tumor progression and metastasis. This experiment provides important pre-clinical data for anti-cancer treatment strategies targeting TRIM40;

[0061] Invasion experiments evaluate the invasive ability of cells by simulating the in vivo environment, which is important for studying the malignancy of tumor cells and their ability to penetrate tissue barriers. This experiment can intuitively reflect how TRIM40 affects the invasive behavior of pancreatic cancer cells, providing key information for understanding its role in promoting or inhibiting tumor invasion. In addition, this has great research value and application prospects for developing new treatments and predicting disease prognosis.

[0062] In this embodiment, a pancreatic cancer cell line overexpressing TRIM40 is cultured according to the culture and treatment method of claim 1; the gene therapy drug to be tested is introduced into the cells; changes in cell proliferation, migration or invasion are detected; and the effect is compared with that of the untreated control group to evaluate the effect of the gene therapy drug on inhibiting the growth of pancreatic cancer cells.

[0063] Furthermore, the method uses a pancreatic cancer cell model that stably overexpresses TRIM40 to provide a reliable screening platform for gene therapy drugs. This model can simulate the state of TRIM40 overexpression in pancreatic cancer patients, making the screened drugs closer to the actual conditions of clinical application and improving the clinical translation potential of the research. Secondly, the method can comprehensively evaluate the inhibitory effect of drugs on the growth of pancreatic cancer cells by introducing the gene therapy drugs to be tested and detecting changes in cell proliferation, migration or invasion. This comprehensive evaluation method helps to identify gene therapy drugs that can not only inhibit cell proliferation but also prevent cell migration and invasion, thereby selecting drug candidate molecules with the best therapeutic effect. In addition, the method also includes comparing the effect with the untreated control group, which ensures the objectivity and accuracy of the evaluation results. By comparing the data of the experimental group and the control group, it can be clearly seen that the specific effects of gene therapy drugs on pancreatic cancer cells provide a quantitative evaluation standard for the efficacy of the drug. Finally, the application of this method is not limited to the screening of a single drug, but can also be used to evaluate the effects of different drug combinations. In cancer treatment, the combined use of multiple drugs can often produce synergistic effects and improve the therapeutic effect. Through this method, researchers can systematically evaluate the effects of different drug combinations on pancreatic cancer cells that overexpress TRIM40, providing a scientific basis for formulating the best treatment plan.

[0064] In this embodiment, pancreatic cancer cells are cultured according to the method of claim 1 and are made to overexpress TRIM40; then, flow cytometry or other cell cycle analysis techniques are used to analyze the cell cycle stages of cells overexpressing TRIM40; and the effect of TRIM40 on the cell cycle of pancreatic cancer cells is evaluated by comparing the differences in cell cycle distribution between cells overexpressing TRIM40 and cells with normal TRIM40 expression levels.

[0065] Furthermore, firstly, this method can analyze in detail the effect of overexpression of TRIM40 on each stage of the cell cycle of pancreatic cancer cells through flow cytometry or other cell cycle analysis techniques. The analysis of this effect is crucial for understanding the role of TRIM40 in the proliferation, division and apoptosis of pancreatic cancer cells. By comparing the differences in cell cycle distribution between cells overexpressing TRIM40 and cells with normal TRIM40 expression levels, we can deeply explore how TRIM40 regulates the biological behavior of pancreatic cancer cells, and provide a theoretical basis for further revealing its potential as a therapeutic target. Secondly, using this method to evaluate the effect of TRIM40 on the cell cycle of pancreatic cancer cells will help identify and verify potential therapeutic targets. If overexpression of TRIM40 can significantly change the cell cycle distribution of pancreatic cancer cells, then TRIM40 is expected to become an attractive therapeutic target, which is of great significance for the development of new anti-cancer drugs or gene therapy. This method is of great significance for the treatment of pancreatic cancer and may provide more effective and personalized treatment options for pancreatic cancer patients. In addition, this method can also be used to evaluate the effectiveness of other potential treatments. By comparing the effects of different treatments on the cell cycle of pancreatic cancer cells overexpressing TRIM40, the most effective treatment strategy can be screened out. The flexibility of this method makes it a new tool for studying pancreatic cancer treatment, which will help accelerate the development of new drugs and the improvement of existing treatments. Finally, this method also has potential clinical application value. By analyzing the cell cycle changes of pancreatic cancer cells, new biomarkers can be provided for patient disease monitoring and efficacy evaluation. For example, if a certain treatment method can cause the expected changes in the cell cycle distribution of pancreatic cancer cells, then this change may become an important indicator for evaluating the treatment effect, which will help doctors more accurately judge the treatment effect, adjust the treatment plan in time, and improve the patient's quality of life and survival rate.

[0066] In this embodiment, pancreatic cancer cells overexpressing TRIM40 prepared according to claim 1 are provided; a series of chemotherapeutic drugs or targeted therapeutic agents with concentration gradients are respectively acted on the cells; the drug sensitivity of different drugs to pancreatic cancer cells overexpressing TRIM40 is evaluated by measuring the cell survival rate, apoptosis rate or expression changes of related markers, and compared with wild-type cells, so as to screen out potential effective therapeutic drugs.

[0067] Furthermore, firstly, by using pancreatic cancer cells that overexpress TRIM40 for drug testing, the biological behavior of tumors that may occur clinically can be more accurately simulated. Since TRIM40 plays an important role in regulating cell proliferation, migration and invasion, the response of these cells to drugs may be closer to the situation in the patient's body, thereby improving the clinical relevance and predictive value of the experimental results. Secondly, this method uses a series of chemotherapy drugs or targeted therapeutic agents with a concentration gradient, allowing researchers to comprehensively evaluate the effects of drugs on cell survival rate, apoptosis rate and related markers. This comprehensive evaluation helps to identify the most effective drugs. or drug combination, which provides a scientific basis for the formulation of personalized treatment plans. Furthermore, comparative analysis with wild-type cells helps to reveal the specific impact of TRIM40 overexpression on the drug sensitivity of pancreatic cancer cells, which not only increases the understanding of the biological function of TRIM40, but also may reveal new therapeutic targets or biomarkers, providing more possibilities for the precision treatment of pancreatic cancer. Finally, the implementation of this method is expected to accelerate the screening and evaluation process of new drugs, shorten the research and development time, and reduce the research and development costs. Through effective screening of in vitro cell lines, ineffective or highly toxic drugs can be quickly excluded, and resources can be concentrated on the most promising candidate drugs.

[0068] Furthermore, compared with HPDE cells, the protein expression level of TRIM40 in MIA PaCa-2 and PANC-1 cells was significantly decreased (P<0.05 or P<0.01). Figure 1 A. TRIM40 protein expression was lower in MIA PaCa-2 cells, and MIA PaCa-2 cells were in good condition, with rapid cell proliferation and easy culture, so MIA PaCa-2 cells were selected for subsequent experiments. Immunofluorescence combined with laser confocal microscopy showed that TRIM40 was mainly distributed in the cytoplasm in MIA PaCa-2 and PANC-1 cells. Figure 1 B.

[0069] Furthermore, after overexpressing TRIM40 in MIA PaCa-2 cells, the expression of TRIM40 was detected by qRT-PCR. The results showed that compared with the control group (Vector group), the expression level of TRIM40 in the TRIM40 overexpression group (LV-TRIM40 group) was significantly increased (P<0.05), indicating that TRIM40 was overexpressed in MIA PaCa-2 cells. Figure 2 .

[0070] Furthermore, CCK-8 assay was used to detect cell proliferation ability. Compared with the control group, the proliferation activity of MIA PaCa-2 cells in the LV-TRIM40 group was significantly reduced (P<0.01). Figure 3A. The results of the plate clone formation experiment showed that the number of MIA PaCa-2 cell clones in the LV-TRIM40 group was significantly reduced compared with the control group. Figure 3 B;

[0071] Furthermore, 48 hours after scratching, compared with the control group, the scratch distance and area of ​​MIA PaCa-2 cells in the LV-TRIM40 group were wider, and the scratch healing ability was significantly reduced. Figure 4 ;

[0072] Furthermore, the results of Transwell assay showed that the migration and invasion abilities of MIA PaCa-2 cells in the LV-TRIM40 group were significantly reduced compared with those in the control group (P<0.01 or P<0.001). Figure 5 .

[0073] The working principle and use process of the present invention:

[0074] First, during the culture and treatment stage of pancreatic cancer cells, it is necessary to select pancreatic cancer cell lines such as MIA PaCa-2 or PANC-1 and culture them in DMEM medium containing 10% fetal bovine serum and 1% penicillin-streptomycin. After the cells grow to a certain density, cells in the logarithmic growth phase are inoculated. This step ensures the consistency of the physiological state of the cells used in the experiment, reduces experimental errors, and improves experimental efficiency and reliability. The next step is to construct a stable cell line. By introducing the TRIM40 gene into pancreatic cancer cells to overexpress TRIM40, cells that stably overexpress TRIM40 can be screened out using specific vectors and screening markers. The third step involves the use of pancreatic cancer cells overexpressing TRIM40 to screen and evaluate gene therapy drugs, which includes introducing the gene therapy drugs to be tested into the cells and then detecting changes in cell proliferation, migration or invasion. The inhibitory effect of drugs on the growth of pancreatic cancer cells is comprehensively evaluated through methods such as CCK8 reagents, clone formation experiments, cell scratch experiments, migration experiments and invasion experiments. These experimental results help to identify those that can not only inhibit cell proliferation, but also The fourth step is cell cycle analysis, using flow cytometry or other cell cycle analysis techniques to analyze the cell cycle stages of cells overexpressing TRIM40. By comparing the differences in cell cycle distribution between cells overexpressing TRIM40 and cells with normal TRIM40 expression levels, the effect of TRIM40 on the cell cycle of pancreatic cancer cells is evaluated. This analysis helps to reveal how TRIM40 regulates the biological behavior of pancreatic cancer cells and provides a theoretical basis for further revealing its potential as a therapeutic target. The last step is an in vitro drug sensitivity test, in which a series of chemotherapy drugs or targeted therapeutic agents with a concentration gradient are applied to pancreatic cancer cells overexpressing TRIM40. By measuring the changes in cell survival rate, apoptosis rate or expression of related markers, the drug sensitivity of different drugs to pancreatic cancer cells is evaluated, and compared with wild-type cells, potential effective therapeutic drugs are screened out. This method allows researchers to comprehensively evaluate the effects of drugs on cell survival rate, apoptosis rate and related markers, identify the most effective drugs or drug combinations, and provide a scientific basis for the formulation of individualized treatment plans.

[0075] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A method for overexpressing TRIM40 to inhibit the proliferation, migration and invasion of pancreatic cancer cells and its application, the method comprising the following steps: A. Provide a pancreatic cancer cell line, such as MIA PaCa-2 or PANC-1, cultured in a freshly prepared DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, cultured at 37° C., 5% CO2, cultured to a certain density, i.e., about 80%, and then taking cells in the logarithmic growth phase for subsequent inoculation treatment; B. Construct a stable cell line. Take MIA PaCa-2 cells in the logarithmic growth phase and inoculate them into a 24-well plate. After culturing at 37°C and 5% CO2 for 16-24 hours, the cells can be infected when the confluence is about 50-60%. After 16 hours, change the medium. 72 hours after infection, observe the fluorescence intensity and determine the transfection efficiency. C. qRT-PCR experiment, total RNA was extracted by Trizol method and reverse transcribed into cDNA using reverse transcription kit (Takara). qRT-PCR was performed in PCR instrument using SYBR Green qPCR method. GAPDH was used as internal reference and 2- ΔΔ The relative expression level was calculated by Ct method; D. Western Blot experiment: MIA PaCa-2 and PANC-1 cells with good growth status were collected, RIPA lysis buffer was added to extract proteins, and the concentration was measured and quantified using the BCA kit; The removed SDS-PAGE gel was fixed in the electrophoresis tank, and 30 ng of total protein was loaded, and electrophoresis was performed at a constant voltage of 160 V for 50 min. The separated proteins were then transferred to the membrane using a wet method, and the transferred PVDF membrane was blocked in 5% skim milk at room temperature for 2 h, washed three times with TBST 10 min / time, and incubated slowly overnight at 4°C with TRIM40 (1:3000) or GAPDH (1:10000) antibodies; After 24 hours, the membrane was removed and washed three times with TBST, and the secondary antibody (1:10000) was added and incubated on a shaker at room temperature for 2 hours, and the gel imager was used for development and imaging. E. Immunofluorescence assay, PANC-1 and MIA PaCa-2 cells were plated in the center of an immunofluorescence dish, cultured for 24 h, washed with PBS for 5 min, washed three times, fixed with paraformaldehyde for 30 min, washed again with PBS, permeabilized with Triton X-100 for 5 min, washed with PBS, blocked with 5% BSA for 2 h, and then incubated with TRIM40 (1:200) antibody prepared with 1% BSA at 4°C overnight; After 24 hours, the cells were washed with PBST, incubated with rabbit secondary antibody (1:500) for 2 hours in the dark, washed three times with PBST, stained nuclei with DAPI for 5 minutes in the dark, washed with PBST, and the expression and localization of TRIM40 were observed under a confocal microscope and photographed. F. Cell proliferation assay: Digest and dilute the cells in the logarithmic growth phase to prepare 1000 cells / well (1x10 4 / ml) of cell suspension was inoculated into 96-well plates at 100ul / well, with at least 3 replicates per group, and cultured in an incubator at 37°C and 5% CO2; After 48 hours, 10ul of CCK8 reagent was added to each well, and the cells were incubated in a dark incubator for 2 hours. The absorbance was measured at 450nm using an ELISA reader for statistical analysis. G. For clone formation experiments, cells in the logarithmic growth phase were digested and diluted to prepare a cell suspension of 1000 cells / well, inoculated into a six-well plate, and cultured in an incubator at 37°C and 5% CO2. The medium was changed every 3 days for 14 consecutive days. After washing with PBS, the cells were fixed with paraformaldehyde for 15 minutes, stained with 1% crystal violet for 15 minutes, and photographed after drying; H. Cell scratch test: Digest and dilute the cells in the logarithmic growth phase to prepare 3.5x10 4 70ul of cell suspension was evenly spread on the wound healing plug. When the cell confluence reached about 90%, the wound healing plug was removed, washed with PBS, and culture medium was added. Pictures were taken at 0h and 24h respectively. I. Migration experiment: Add 1x10 5 Cells suspended in 100ul serum-free medium were added to the lower chamber, and 600ul complete medium was added to the lower chamber. After culturing in an incubator at 37°C and 5% CO2 for 48h, the chamber was removed, washed 3 times with PBS, fixed with 4% paraformaldehyde for 30min, stained with 1% crystal violet for 5min, and the cells that did not pass through the upper chamber were wiped off with a wet cotton swab and washed with PBS. The cells were observed, photographed and counted under an inverted microscope; J. Invasion assay: 100ul of matrix gel was pre-coated on the upper chamber membrane of the Transwell and allowed to stand at 37°C for 2 hours. After solidification, the excess matrix gel was removed. The subsequent steps were the same as those of the migration assay; K. Statistics and analysis: GraphPad Prism 8.0 software was used for statistical analysis, and the data were expressed as mean ± standard deviation. Paired t-test was used for comparison between the two groups, and P < 0.05 was considered statistically significant.

2. The method for screening and evaluating gene therapy drugs for a pancreatic cancer cell line overexpressing TRIM40 according to claim 1, comprising the following steps: According to the culture and treatment method of claim 1, a pancreatic cancer cell line overexpressing TRIM40 is cultured; the gene therapy drug to be tested is introduced into the cells; changes in cell proliferation, migration or invasion are detected; and the effect is compared with that of an untreated control group to evaluate the effect of the gene therapy drug on inhibiting the growth of pancreatic cancer cells.

3. A method for performing cell cycle analysis on a pancreatic cancer cell model overexpressing TRIM40 according to claim 2, the method comprising: Pancreatic cancer cells are cultured according to the method of claim 1 and are made to overexpress TRIM40; then, the cell cycle stages of the cells overexpressing TRIM40 are analyzed using flow cytometry or other cell cycle analysis techniques; and the effect of TRIM40 on the cell cycle of pancreatic cancer cells is evaluated by comparing the differences in cell cycle distribution between cells overexpressing TRIM40 and cells with normal TRIM40 expression levels.

4. The use of a pancreatic cancer cell overexpressing TRIM40 in an in vitro drug sensitivity test according to claim 3, comprising: Provide pancreatic cancer cells overexpressing TRIM40 prepared according to claim 1; subject the cells to a series of chemotherapeutic drugs or targeted therapeutic agents with different concentration gradients; evaluate the drug sensitivity of pancreatic cancer cells overexpressing TRIM40 by measuring cell survival rate, apoptosis rate or expression changes of related markers, and compare with wild-type cells, so as to screen out potential effective therapeutic drugs.

Citation Information

Cited By

  • Pancreatic cancer resistant drug screening platform and method based on intelligent tablet phone

    CN120147831A